The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether the excess risk of death and cardiovascular events among patients with type 2 diabetes could be reduced or eliminated. METHODS: In a cohort study, we included 271,174 patients with type 2 diabetes who were registered in the Swedish National Diabetes Register and matched them with 1,355,870 controls on the basis of age, sex, and county. We assessed patients with diabetes according to age categories and according to the presence of five risk factors (elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, albuminuria, smoking, and elevated blood pressure). Cox regression was used to study the excess risk of outcomes (death, acute myocardial infarction, stroke, and hospitalization for heart failure) associated with smoking and the number of variables outside target ranges. We also examined the relationship between various risk factors and cardiovascular outcomes. RESULTS: The median follow-up among all the study participants was 5.7 years, during which 175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of outcomes decreased stepwise for each risk-factor variable within the target range. Among patients with diabetes who had all five variables within target ranges, the hazard ratio for death from any cause, as compared with controls, was 1.06 (95% confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial infarction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 (95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside the target range was the strongest predictor of stroke and acute myocardial infarction; smoking was the strongest predictor of death. CONCLUSIONS: Patients with type 2 diabetes who had five risk-factor variables within the target ranges appeared to have little or no excess risk of death, myocardial infarction, or stroke, as compared with the general population. (Funded by the Swedish Association of Local Authorities and Regions and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when all major cardiovascular risk factors are treated to within the target ranges, people with type 2 diabetes have risk of death, MI, or stroke similar to that of the general population (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among persons with type 2 diabetes (T2D), cardiovascular risk and mortality are dependent on the number of uncontrolled risk factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the evidence from prospective intervention studies to support comprehensive ASCVD risk factor reduction, a large cohort study confirmed no or only marginally increased mortality, MI, and stroke risk compared with the general population when all major cardiovascular risk factors are managed to goal levels in people with type 2 diabetes (6).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Hypertriglyceridemia is indirectly linked with changes in HDL-C and LDL-C composition that are conducive to accelerated atherogenesis.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [313]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite these newer therapies, the risk of kidney failure remains high, particularly in those whose risk factors are insufficiently controlled.6,7”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with advanced disease, e.g.T2DM and established microalbuminuria, an intensive, target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) resulted in 50% fewer microvascular and macrovascular events after 7.8 years of follow-up.361”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [361]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citation
Cited by
Sorted by citations
Items 701–800 of 999
Heavier but Healthier — Diabetes and Smoking Cessation
Schroeder, S. A. (2018) · New England Journal of Medicine · doi:10.1056/nejme1809004 · Cited by 7
Larsson, H. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2279608 · Cited by 7
van de Vijver, W. R., Hennecken, J., Lagogiannis, I., del Villar, C. P., Flores, C. H., Douek, P., Segev, A., Hovingh, G. K., Išgum, I., Winter, M. M., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512442 · Cited by 6
Almutairi, T., Dargham, S. R., Jayyousi, A., Suwaidi, J. M. S. A., & Khalil, C. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318774 · Cited by 8
Zhang, Z., Wang, C., Zhao, L. Y., Wang, Z., Zhou, X., Yang, W., & Meng, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16293 · Cited by 7
Prevalence and Predictors of Silent Myocardial Ischemia in Diabetic Patients
Manan, H. A., Chishti, H. R., & Hewlett, F. D. (2025) · Cureus · doi:10.7759/cureus.82407 · Cited by 6
Surrogate endpoints in diabetic kidney disease: current perspectives and future directions
Cao, C., Zhang, J., Ma, T., Miao, J., & Sun, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1557813 · Cited by 6
Type 2 diabetes specialist care in Italy in the AMD Annals initiative 2024: The path is traced
Russo, G. T., Cosmo, S. D., Nicolucci, A., Manicardi, V., Rocca, A., Lucisano, G., Rossi, M. C., Bartolo, P. D., Cianni, G. D., & Candido, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112273 · Cited by 6
Abizaid, A., Mehran, R., Oliva, A., Chamié, D., Staico, R., Malik, F., Vink, M., Kurniadi, A., Cao, D., Capranzano, P., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02157-9 · Cited by 6
Long term risk of heart failure in individuals with childhood-onset type 1 diabetes
Guo, J. S., Costacou, T., & Orchard, T. J. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108233 · Cited by 6
Wang, X., Ma, H., Li, X., Liang, Z., Fonseca, V. A., & Qi, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15443 · Cited by 6
Mattsson, K., Pihlsgård, M., Enhörning, S., & Timpka, S. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22081 · Cited by 7
Decoding cardiovascular risks: analyzing type 2 diabetes mellitus and ASCVD gene expression
Zhang, Y., Ji, L., Yang, D., Wu, J., & Yang, F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383772 · Cited by 6
Loneliness, social isolation and incident chronic kidney disease among patients with diabetes
Tang, R., Zhou, J. S., Wang, X., Ma, H., Li, X., Heianza, Y., & Qi, L. (2024) · General Psychiatry · doi:10.1136/gpsych-2023-101298 · Cited by 6
Influence of multiple risk factor control level on cardiovascular outcomes in hypertensive patients
Peng, X., Zhuang, M., Song, Q., Bai, J., & Cai, J. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae056 · Cited by 8
Tabesh, M., Sacre, J. W., Mehta, K., Chen, L., Sajjadi, S. F., Magliano, D. J., & Shaw, J. E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15938 · Cited by 7
Monteiro, M., Ferreira‐Duarte, M., Vitorino-Oliveira, C., Costa-Pires, J., Oliveira, S., Matafome, P. N., Morato, M., Dias‐Pereira, P., Costa, V. M., & Duarte‐Araújo, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212115 · Cited by 7
Yang, H., Zeng, M., Fan, T., Chen, H., Fang, X., Li, Z. A., Wang, X., Hunter, D. J., Ding, C., & Zhu, Z. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.02.004 · Cited by 8
Oliveira, A. R., Chevalier, C., Wargny, M., Pakulska, V., Caradeuc, C., Cloteau, C., Letertre, M. P. M., Giraud, N., Bertho, G., Bigot‐Corbel, E., et al. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf035 · Cited by 6
Subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus
Tsvetkov, V. A., Крутиков, Е. С., & Chistyakova, S. (2020) · Problems of Endocrinology · doi:10.14341/probl12359 · Cited by 6
A Systematic Mapping Study on the Risk Factors Leading to Type II Diabetes Mellitus
Musafer, K. N. J., Huyop, F., Ewadh, M., Supriyanto, E., & Rava, M. (2020) · Karbala International Journal of Modern Science · doi:10.33640/2405-609x.1677 · Cited by 8
Glucose-lowering therapy in patients undergoing percutaneous coronary intervention
Johansson, I., Dicembrini, I., Mannucci, E., & Cosentino, F. (2021) · EuroIntervention · doi:10.4244/eij-d-20-01250 · Cited by 6
Enguita‐Germán, M., Tamayo, I., Galbete, A., Librero, J., Cambra, K., & Ibáñez, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312370 · Cited by 6
Forecasting Heart Failure Risk in Diabetes
Verma, S., Pandey, A., & Bhatt, D. L. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.011 · Cited by 6
Brunetti, V. C., Yu, O. H. Y., Platt, R. W., & Filion, K. B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14802 · Cited by 6
Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes
Gregers, M. C. T., Schou, M., Jensen, M. T., Jensen, J., Petrie, M. C., Vilsbøll, T., Goetze, J. P., Rossing, P. R., & Jørgensen, P. G. (2022) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2022.2095435 · Cited by 6
Orsi, E., Solini, A., Bonora, E., Vitale, M., Garofolo, M., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Laviola, L., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01942-8 · Cited by 7
Wright, W. L., Urquhart, S., & Brunton, S. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319231153599 · Cited by 6
The change of non-alcoholic fatty liver disease is associated with risk of incident diabetes
Chen, C., Zhang, Y., Fan, Y., Ying, Z., Su, Q., Li, X., & Qin, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1108442 · Cited by 6
Jong, C.-B., Lu, T. E., Chen, T.-Y., Chen, C., Liao, M., Lin, I.-C., & Chen, J. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131195 · Cited by 6
Temporal trends in cardiovascular outcomes and costs among patients with type 2 diabetes
Williams, B. A., RAJPURA, J. R., Paprocki, Y., Kumar, N., Voyce, S. J., Brady, J. P., & Chang, A. R. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.07.012 · Cited by 7
Abdel‐Rahman, N., Manor, O., Cohen, A. D., Elran, E., Golan‐Cohen, A., Krieger, M., Paltiel, O., Valinsky, L. J., Ben‐Yehuda, A., & Calderon‐Margalit, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302422 · Cited by 6
Xu, W., Li, X., Tse, G., Chan, J. S. K., Wu, S., & Liu, T. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102737 · Cited by 6
Long-term follow-up of intensive glycaemic control in type 2 diabetes
Patel, K. V., & McGuire, D. K. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0241-y · Cited by 6
Self-citationUse of the Burden of Diabetes Mellitus Score for Cardiovascular Disease Risk Assessment
Farjo, P. D., Barghouthi, N., Chima, N. R., Desai, A., Fang, W., Giordano, J., & Bianco, C. M. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.027 · Cited by 6
Impact of Obesity in Hospitalized Patients with Heart Failure: A Nationwide Cohort Study
Gajulapalli, R. D., Kadri, A. N., Gad, M. M., Chahine, J., Nusairat, L., & Rader, F. (2020) · Southern Medical Journal · doi:10.14423/smj.0000000000001174 · Cited by 6
Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6
Kiburg, K., MacIsaac, A. I., Wilson, A., Sundararajan, V., & MacIsaac, R. J. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51101 · Cited by 6
Razaghizad, A., Sharma, A., Ni, J., Ferreira, J. P., White, W. B., Mehta, C. R., Bakris, G. L., & Zannad, F. M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14867 · Cited by 6
Jatoi, N.-A., Elamin, Y., Said, A. H., Al-Namer, B., Al-Muallim, F. A., Al-Nemer, F. F., & Al-Halal, F. M. (2022) · Cureus · doi:10.7759/cureus.29489 · Cited by 6
Lin, L., Hwu, C., Chu, C., Won, J. G. S., Chen, H.-S., & Chang, L.-H. (2019) · Medicine · doi:10.1097/md.0000000000015556 · Cited by 6
Milà, L., Barrabés, J. A., Lidón, R. M., Sambola, A., Bañeras, J., Oristrell, G., Rafecas, A., & David Garcia-dorado, A. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.06.012 · Cited by 6
Josefsson, C., Liljeroos, T., Hellgren, M. I., Pöder, U., Hedström, M., & Olsson, E. M. G. (2024) · JMIR Formative Research · doi:10.2196/46222 · Cited by 7
Kotseva, K., Jennings, C. S., Bassett, P., Adamska, A., Hobbs, R. F., & Wood, D. (2024) · Open Heart · doi:10.1136/openhrt-2024-002704 · Cited by 5
Guraka, A., Sreedharan, S., Arasaradnam, R. P., Tripathi, G., & Kermanizadeh, A. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae172 · Cited by 5
Zhou, H., Zhu, X., Zhang, Y., Xu, W., & Li, S. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03488-1 · Cited by 5
Fabris, C., Rizzo, E., Bertolissi, S., Casatta, L., Pavan, M., & Toniutto, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093155 · Cited by 6
Cheng, Z., Xu, W., Luo, J., Zeng, X., Zeng, Q., Cao, G., Liu, G., & Xiao, C. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101339 · Cited by 5
Okechukwu, U. C., Ugwu, T. E., Abonyi, M. C., Chukwubuzo, O. T., Nnaji, T. O., & Ume, N. M. (2023) · Annals of Clinical and Biomedical Research · doi:10.4081/acbr.2023.243 · Cited by 6
Sujata, S., Gayathri, B., & Thakur, R. (2023) · Value in Health Regional Issues · doi:10.1016/j.vhri.2023.09.009 · Cited by 5
Jiang, X., Chen, Q., Chen, X., Sun, Q., Jing, F., Zhang, H., Xu, J., Li, X., & Guan, Q. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03867-2 · Cited by 5
Ramírez‐García, D., Fermín‐Martínez, C. A., Sánchez-Castro, P., Núñez-Luna, A., Basile‐Alvarez, M. R., Fernández‐Chirino, L., Vargas‐Vázquez, A., Díaz-Sánchez, J. P., Kammar‐García, A., Almeda‐Valdés, P., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-19536-0 · Cited by 5
Diabetes complications in people with alcohol use disorder and type 2 diabetes
Cook, S., Saxena, S. K., Mathur, R., Beaney, T. E., Gnani, S., Neves, A. L., Maini, A., Parekh, R., Walters, K. R., Osborn, D., et al. (2025) · BJGP Open · doi:10.3399/bjgpo.2024.0133 · Cited by 5
Cui, W., Li, Y., Li, N., Chan, K. K., & Piao, C. (2025) · Endocrinology · doi:10.1210/endocr/bqaf040 · Cited by 5
SGLT2 inhibitors for primary prevention of cardiovascular events
Raz, I., Cernea, S., & Cahn, A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.13004 · Cited by 5
Eliminating Missed Opportunities for Patients with Type 2 Diabetes
Rajagopalan, S., Pronovost, P. J., & Neeland, I. J. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.003 · Cited by 5
Obaya, J. C., Jiménez, S., Osoro, I. A., Barrera, F., Soidán, F. J. G., & Cuenca, A. M. C. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.07.009 · Cited by 5
Gimeno-Orna, J. A., Padial, L. R., Anguita-Sánchez, M. P., Barrios, V., Muñiz, J., & Pérez, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204634 · Cited by 5
Williams, B. A., Brady, J. P., Voyce, S. J., Kumar, N., Paprocki, Y., & RAJPURA, J. R. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14686 · Cited by 5
Implementation of Cardiometabolic Centers and Training Programs
Taha, M. B., Rao, N., Vaduganathan, M., Cainzos‐Achirica, M., Nasir, K., & Patel, K. V. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01459-y · Cited by 5
Ko, T., Lin, T., Hsu, J., Yang, Y., Chuang, S.-L., Lin, L., Kao, H., & Ho, Y. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110050 · Cited by 5
Sicras‐Mainar, A., Sicras-Navarro, A., Palacios, B., Mutiozabal, M. S., Blanco, J., Hormigo, A., Manito, N., Arroyo, R. A., & Botana-López, M. A. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.07.005 · Cited by 5
Jiang, P., Suzuki, H., & Obi, T. (2023) · Health and Technology · doi:10.1007/s12553-023-00730-w · Cited by 5
Ma, L., Cai, B., Qiao, M.-L., Fan, Z.-X., Fang, L.-B., Wang, C., & Liu, G.-Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1128022 · Cited by 5
Obesity management for the hepatologist—What to do, how to do it and why?
Watt, K. D. S., Paul, S., Khan, M. Q., Siddiqui, M. S., Lam, J., Diwan, T. S., & Camilleri, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000598 · Cited by 5
Bielinskyi, M. V., Seredyuk, N. M., Fedorov, S. V., Herashchenko, A. S., & Volynskyi, D. A. (2023) · EMERGENCY MEDICINE · doi:10.22141/2224-0586.19.5.2023.1609 · Cited by 7
Cortés, M., Lorenzo, Ó., Lumpuy‐Castillo, J., Martínez-Albaladejo, S., Urquía, M. T., Pello, A. M., Becerra, A. J. B., Orejas, M., Navas, M. Á., Macia, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206698 · Cited by 5
Pérez, A., Redondo‐Antón, J., Romera, I., Lizán, L., Santos, M. R., Díaz‐Cerezo, S., & Orozco‐Beltrán, D. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01503-4 · Cited by 7
Palanca, A., Ampudia‐Blasco, F. J., Calderón, J. M., Saurí, I., Martínez‐Hervás, S., Trillo-Mata, J. L., Redón, J., & Real, J. T. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111071 · Cited by 6
Tabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzı́k, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
Kong, Y.-H., Chen, S.-R., Ma, N., Chen, Z.-K., Karoli, P. M., Niyi, J. L., Fan, P.-Y., Fink, G., Kwete, X., Wehrmeister, F. C., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102583 · Cited by 12
Zareini, B., Sørensen, K. K., Pedersen‐Bjergaard, U., Fosbøl, E. L., Køber, L., & Torp-Pedersen, C. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13560 · Cited by 4
Tanashyan, M. M., & Антонова, К. В. (2025) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1359 · Cited by 5
Zaharia, O., & Szendrödi, J. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0451-2 · Cited by 5
Accelerated atherosclerotic cardiovascular risk in type 1 diabetes mellitus: Time for a new idea?
Rao, A. D., Vaz, C. L., & Williams, K. J. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.04.207 · Cited by 5
Padovani, C., Arruda, R. M. D. C., & Sampaio, L. M. M. (2019) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2019-0027 · Cited by 6
Practical use of electronic health records among patients with diabetes in scientific research
Shen, Y., Zhou, J., & Hu, G. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000784 · Cited by 5
The role of sodium glucose co-transporter inhibitors in heart failure prevention
Garla, V. V., Subauste, A. R., Butler, J., & Lien, L. F. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107811 · Cited by 5
Viktorínová, A., Fábryová, Ľ., Malickova, D., Choudhury, S., & Krizko, M. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0087 · Cited by 6
Sicras‐Mainar, A., Sicras-Navarro, A., Palacios, B., Mutiozabal, M. S., Blanco, J., Hormigo, A., Manito, N., Arroyo, R. A., & Botana-López, M. A. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.08.002 · Cited by 5
Patoulias, D., Papadopoulos, C. E., Kassimis, G., Karagiannis, A. I., & Doumas, M. N. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.08.009 · Cited by 5
Hassanein, M. M., Akbar, M. A. J., Alshamiri, M. Q., Amir, A., Amod, A., Chudleigh, R. A., Elhadd, T. A., Heshmat, H., Jibani, M. M., & Saleh, Y. M. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01282-4 · Cited by 5
Rosén, A., Otten, J., Stomby, A., Vallin, S., Wennberg, P., & Brunström, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062172 · Cited by 6
Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes
Motairek, I. K., & Al-Kindi, S. G. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.002 · Cited by 5
Eliasson, B., Ekelund, J., Holmberg, C. N., Wolden, M. L., Matthiessen, K. S., & James, S. K. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac308 · Cited by 5
Self-citationThöni, S., Keller, F., Denicolò, S., Eder, S., Buchwinkler, L., Rosivall, L., Więcek, A., Mark, P. B., Rossing, P. R., Heerspink, H. J. L., et al. (2023) · Kidney & Blood Pressure Research · doi:10.1159/000528438 · Cited by 5
Garofolo, M., Penno, G., Solini, A., Orsi, E., Vitale, M., Resi, V., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.05.034 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 5
Collins, S. É., Lethebe, B. C., Williamson, T. S., & McAlister, F. A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.114 · Cited by 4
Ibrahim, L. B., Idowu, P. F., Moses, O. A., Alabi, M. A., & Ajani, E. O. (2021) · Acta chimica slovenica · doi:10.17344/acsi.2020.6212 · Cited by 5
Gain in survival after metabolic–bariatric surgery
Mingrone, G., & Bornstein, S. R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00952-1 · Cited by 5
Changing the diabetes treatment paradigm from glucose control to cardiorenal protection
Ekanayake, P. S., & Mudaliar, S. R. D. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_3114_21 · Cited by 5
Ahmad, A., Lim, L., Morieri, M. L., Tam, C., Cheng, F., Chikowore, T., Dudenhöffer‐Pfeifer, M., Fitipaldi, H., Huang, C., Kanbour, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2929263/v1 · Cited by 5
Jung, I., Han, K.-D., Moon, S. J., Kwon, H., Park, S. E., Rhee, E.-J., & Lee, W.-Y. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110819 · Cited by 4
Shi, S., Li, X., Chen, Y., Li, J., & Dai, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70044 · Cited by 4
Yin, J., Li, T., Yu, Z., Yu, L., Bian, L., Xiang, B., & Gu, X. (2025) · Heart · doi:10.1136/heartjnl-2024-325355 · Cited by 4
Chen, Y., Wang, J., Feng, X., Qian, X., He, S., An, Q., Yin, X., Wang, X., An, Y., Gong, Q., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2675 · Cited by 4
Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies
Chen, X., Li, W. S., Zheng, J.-W., Huang, M., Wang, J., & Wu, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630686 · Cited by 6
Jiang, Z.-Z., Jiang, Y., Wang, Y., Zhou, Y., Peng, R.-L., Cai-ye, M., & Liu, X. (2025) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-025-03247-6 · Cited by 4
Coronary Stent Failure in Patients With Diabetes: A Nationwide Observational Study From SWEDEHEART
Santos‐Pardo, I., Andersson, M., Hofmann, R., & Nyström, T. (2025) · Diabetes Care · doi:10.2337/dc25-1624 · Cited by 4
Metadata
- Authors
- Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A.-M., Zethelius, B., Miftaraj, M., McGuire, D. K., Rosengren, A., & Gudbjörnsdottir, S.
- Affiliations
- Uppsala University (SE)
- From the Department of Molecular and Clinical Medicine, Institute of Medicine (Aidin Rawshani, Araz Rawshani, B.E., A. Rosengren, S.G.), and the Health Metrics Unit, Sahlgrenska Academy (S.F.), University of Gothenburg, and the Swedish National Diabetes Register, Center of Registers in Region (Aidin Rawshani, Araz Rawshani, S.F., B.E., A.-M.S., M.M., S.G.), Gothenburg, and the Department of Public Health and Caring Sciences–Geriatrics, Uppsala University, and the Swedish Medical Products Agency,...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-08-16
- Volume
- 379
- Issue
- 7
- Pages
- 633-644
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2887185538
- Cited by
- 1,475
- References
- 22
- Citations by year
- 2026: 158 · 2025: 172 · 2024: 178 · 2023: 175 · 2022: 197 · 2021: 219 · 2020: 210 · 2019: 141 · 2018: 20
- FWCI
- 116.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk factors, mortality, acute myocardial infarction, stroke, heart failure hospitalization, HbA1c, LDL cholesterol, albuminuria, smoking, blood pressure, Swedish National Diabetes Register, matched cohort comparison
- MeSH terms
- Adult, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypercholesterolemia, Hypertension, Male, Middle Aged, Myocardial Infarction, Risk Factors, Smoking, Sweden, Cohort Studies, Body Mass Index, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
